ERBB2 and breast carcinoma: Around 20–25% of breast cancer is characterized as human epidermal growth factor receptor 2 (HER2) overexpression, which predicts a more aggressive biological behavior, a higher risk of early recurrence and metastasis, and a poor prognosis of patients [4].